De Novo
DEN160006: everlinQ endoAVF System
FDA De Novo · tva medical, inc. · decided Jun 22, 2018
Key facts
| De Novo number | DEN160006 |
|---|---|
| Device name | everlinQ endoAVF System |
| Applicant | tva medical, inc. |
| Product code | PQK |
| Date received | Feb 3, 2016 |
| Decision date | Jun 22, 2018 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Cardiovascular |
| FEI number | 3011392541 |
At a glance
- 1–9 Later 510(k)s citing this De Novo
- None UDI device identifiers (GUDID)
- 10–99 MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: